Buprenorphine
End Stage Renal Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the End Stage Renal Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LIDOCAINE The First People's Hospital of Lianyungang | Phase 4 | BB |
ROPIVACAINE The First People's Hospital of Lianyungang | Phase 4 | BB |
FLUOXETINE University of Arkansas | Phase 4 | BB |
WARFARIN Nicholas Carlson | Phase 4 | BB |
Capsaicin Emma Aitken | Phase 4 | BB |
View all 24 →
Same molecule, other indications
Buprenorphine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →